Compare Qurate Retail Inc Series A (QVCAQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qurate Retail Inc Series A vs Zoetis Inc — how do they compare? Qurate Retail Inc Series A trades at $0.04 (market cap $653.75K), while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 48321.2× Qurate Retail Inc Series A's market cap, and Zoetis Inc pays a 2.81% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| QVCAQ | ZTS | |
|---|---|---|
Market Cap | $653.75K | $31.59B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.03 | $156.76 |
52-Week Low | $0.05 | $71.91 |
Enterprise Value | $4.73B | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QVCAQ trades at $0.0515, down 12.12% in the past 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of $2.44 billion in 2025 on revenue of $9.23 billion, with negative profit margins and declining revenue trends. Cash flow improved due to financing activities, but negative equity and high debt-to-asset ratios of 77.57% highlight financial stress. Recent news includes QVC celebrating 40 years of live shopping innovation with a TikTok Shop Super Brand Day (PRNewsWire, May 28, 2026).
The outlook remains challenging due to persistent losses, high leverage, and revenue declines. Investment opportunities are limited given weak fundamentals, though low P/E and P/B ratios may attract value hunters. Key risks include bankruptcy concerns from negative equity, competitive pressures in retail, and inability to achieve profitability. Analyst sentiment is cautious, with no bullish indicators supporting near-term recovery.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
